Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Non-Current Assets (2022 - 2025)

Historic Non-Current Assets for Addex Therapeutics (ADXN) over the last 4 years, with Q3 2025 value amounting to $6.2 million.

  • Addex Therapeutics' Non-Current Assets fell 3356.77% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.2 million, marking a year-over-year decrease of 3356.77%. This contributed to the annual value of $8.1 million for FY2024, which is 168894.66% up from last year.
  • According to the latest figures from Q3 2025, Addex Therapeutics' Non-Current Assets is $6.2 million, which was down 3356.77% from $7.1 million recorded in Q2 2025.
  • In the past 5 years, Addex Therapeutics' Non-Current Assets registered a high of $10.0 million during Q2 2024, and its lowest value of $45125.0 during Q1 2024.
  • Its 4-year average for Non-Current Assets is $3.4 million, with a median of $560141.6 in 2022.
  • Its Non-Current Assets has fluctuated over the past 5 years, first crashed by 8901.01% in 2024, then soared by 1539725.9% in 2025.
  • Addex Therapeutics' Non-Current Assets (Quarter) stood at $470316.2 in 2022, then fell by 2.37% to $459148.9 in 2023, then surged by 1674.36% to $8.1 million in 2024, then dropped by 23.8% to $6.2 million in 2025.
  • Its last three reported values are $6.2 million in Q3 2025, $7.1 million for Q2 2025, and $7.0 million during Q1 2025.